Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (5)

1

Prognostic value of minimal residual disease negativity in myeloma : combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

enthalten in: Blood | 2022

von Cavo, M. | San-Miguel, J. | Usmani, S. | +24

CommentIn: Blood. 2022 Feb 10;139(6):799-802. - PMID 35142848

2

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

enthalten in: Blood | 2019

von Usmani, S. | Nahi, H. | Mateos, M. | +13

3

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

enthalten in: Blood | 2016

von Krejcik, J. | Casneuf, T. | Nijhof, I. | +11

CommentIn: Blood. 2016 Jul 21;128(3):318-9. - PMID 27445408

4

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

enthalten in: Blood | 2016

von Zweegman, S. | van der Holt, B. | Mellqvist, U. | +25

5

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma

enthalten in: Blood | 2006

von van de Donk, N. | Kröger, N. | Hegenbart, U. | +12

1
[1]